Clinical Pharmacokinetics

Rivaroxaban

Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention

W. Mueck, et al.

Supplemental Digital Content

This Supplemental Digital Content contains the figures referred to in the full version of this article, which can be found online at http://adisonline.com/pharmacokinetics

© 2011 Adis Data Information BV. All rights reserved.
Figure S-1. Bootstrap results (n = 1000) of estimation of various parameters in the final pharmacokinetic model (the thick vertical lines show the results obtained with the final pharmacokinetic model in the original dataset). CI = clearance; ILV = interindividual; LBM = lean body mass; SCRE = serum creatinine; V = volume of distribution.
Figure S-2a. Visual predictive check of the final pharmacokinetic model for the 10, 20, 30 and 40 mg doses on days 1 and 21, based on \( n = 200 \) sub-problem simulations. \( C_p \) = plasma concentration; \( TAD \) = time after dose.
Figure S-2b. Visual predictive check of the final pharmacokinetic model for the 20, 30 and 40 mg doses on days 1, 43 and 84, based on $n = 200$ sub-problem simulations. $C_p$ = plasma concentration; $TAD$ = time after dose.